Safety and tolerability of continuous inhaled iloprost in critically ill pediatric pulmonary hypertension patients: A retrospective case series

Abstract Inhaled iloprost (iILO) has shown efficacy in treating patients with hypoxic lung disease and pulmonary hypertension, inducing selective pulmonary vasodilation and improvement in oxygenation. However, its short elimination half‐life of 20–30 min necessitates frequent intermittent dosing (6–...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Elizabeth Colglazier, Angelica J. Ng, Claire Parker, David Woolsey, Raymond Holmes, Allison Dsouza, Jasmine Becerra, Leah Stevens, Hythem Nawaytou, Roberta L. Keller, Jeffrey R. Fineman
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2023-07-01
coleção:	Pulmonary Circulation
Assuntos:	Iloprost prostacyclin pulmonary hypertension pulmonary vascular disease
Acesso em linha:	https://doi.org/10.1002/pul2.12289
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!